FDA Grants Orphan Drug Status to GRI Bio's IPF Drug GRI-0621, Offering 7 Years Exclusivity
GRI is trading near its 52-week low of $1.97 (13% above the low) on elevated volume (7.0× avg).
Summary
GRI Bio secured FDA Orphan Drug Designation for its lead candidate, GRI-0621, for Idiopathic Pulmonary Fibrosis. This follows positive Phase 2a clinical data for the drug announced on May 14th. The designation is a significant regulatory milestone, offering potential for seven years of U.S. market exclusivity upon approval, along with tax credits and fee waivers. This development is crucial for the micro-cap company, especially given its recent Q1 2026 report which included a going concern warning and substantial dilution.
At the time of this announcement, GRI was trading at $2.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $1.97 to $80.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.